RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

TOKYO--(BUSINESS WIRE)--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD). The TEMPURA IST was an open-label, uncontrolled, small study (n=5) designed to evaluate the efficacy and safet